Literature DB >> 11730323

The Raf/MEK/ERK pathway: new concepts of activation.

C Peyssonnaux1, A Eychène.   

Abstract

The Raf/MEK/ERK signaling was the first MAP kinase cascade to be characterized. It is probably one of the most well known signal transduction pathways among biologists because of its implication in a wide variety of cellular functions as diverse -and occasionally contradictory- as cell proliferation, cell-cycle arrest, terminal differentiation and apoptosis. Discovery and understanding of this pathway have benefited from the combination of both genetic studies in worms and flies and biochemical studies in mammalian cells. However, ten years after, this field is still under debate and new molecular partners in the cascade continue to increase the complexity of its regulation. This review deals with the emergence of new concepts in the activation and regulation of the Raf/MEK/ERK module. In particular, the preponderant role of B-Raf is underlined, and the role of novel regulators such as KSR is discussed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11730323     DOI: 10.1016/s0248-4900(01)01125-x

Source DB:  PubMed          Journal:  Biol Cell        ISSN: 0248-4900            Impact factor:   4.458


  198 in total

Review 1.  Modern trends into the epidemiology and screening of ovarian cancer. Genetic substrate of the sporadic form.

Authors:  Maria Koutsaki; Apostolos Zaravinos; Demetrios A Spandidos
Journal:  Pathol Oncol Res       Date:  2011-12-09       Impact factor: 3.201

2.  Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2.

Authors:  Jaishri O Blakeley; D Gareth Evans; John Adler; Derald Brackmann; Ruihong Chen; Rosalie E Ferner; C Oliver Hanemann; Gordon Harris; Susan M Huson; Abraham Jacob; Michel Kalamarides; Matthias A Karajannis; Bruce R Korf; Victor-Felix Mautner; Andrea I McClatchey; Harry Miao; Scott R Plotkin; William Slattery; Anat O Stemmer-Rachamimov; D Bradley Welling; Patrick Y Wen; Brigitte Widemann; Kim Hunter-Schaedle; Marco Giovannini
Journal:  Am J Med Genet A       Date:  2011-12-02       Impact factor: 2.802

Review 3.  ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions.

Authors:  Philippe P Roux; John Blenis
Journal:  Microbiol Mol Biol Rev       Date:  2004-06       Impact factor: 11.056

4.  Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway.

Authors:  Jin H Li; Wansheng Wang; Xiao R Huang; Matthew Oldfield; Ann M Schmidt; Mark E Cooper; Hui Y Lan
Journal:  Am J Pathol       Date:  2004-04       Impact factor: 4.307

5.  Circadian regulation of cGMP-gated channels of vertebrate cone photoreceptors: role of cAMP and Ras.

Authors:  Gladys Y-P Ko; Michael L Ko; Stuart E Dryer
Journal:  J Neurosci       Date:  2004-02-11       Impact factor: 6.167

6.  Schwann cell dedifferentiation is independent of mitogenic signaling and uncoupled to proliferation: role of cAMP and JNK in the maintenance of the differentiated state.

Authors:  Paula V Monje; Jennifer Soto; Ketty Bacallao; Patrick M Wood
Journal:  J Biol Chem       Date:  2010-07-15       Impact factor: 5.157

7.  Distribution of some activating KRAS and BRAF mutations in Slovene patients with colorectal cancer.

Authors:  Alenka Ličar; Petra Cerkovnik; Srdjan Novaković
Journal:  Med Oncol       Date:  2010-07-20       Impact factor: 3.064

8.  DARPP-32 is required for MAPK/ERK signaling in thyroid cells.

Authors:  Ana Chocarro-Calvo; Miguel A Zaballos; Pilar Santisteban; Custodia García-Jiménez
Journal:  Mol Endocrinol       Date:  2012-02-02

9.  Analysis of the BRAF(V600E) Mutation in Central Nervous System Tumors.

Authors:  Jae Kyung Myung; Hwajin Cho; Chul-Kee Park; Seung-Ki Kim; Se-Hoon Lee; Sung-Hye Park
Journal:  Transl Oncol       Date:  2012-12-01       Impact factor: 4.243

10.  BRAFV600E mutation in the pathogenesis of a large series of papillary thyroid carcinoma in Czech Republic.

Authors:  V Sykorova; S Dvorakova; A Ryska; J Vcelak; E Vaclavikova; J Laco; D Kodetova; R Kodet; A Cibula; J Duskova; A Hlobilkova; J Astl; D Vesely; J Betka; J Hoch; S Smutny; J Cap; P Vlcek; Z Novak; B Bendlova
Journal:  J Endocrinol Invest       Date:  2009-12-04       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.